Results 81 to 90 of about 4,367 (184)

Efficacy of Interleukin‐12/23 and Interleukin‐23 Inhibitors for Moderately to Severely Active Crohn's Disease in Advanced Treatment Failure Populations: Systematic Review and Network Meta‐Analysis

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims Earlier trials of advanced treatments indicated for moderately to severely active Crohn's disease used predominantly re‐randomized induction responder designs, whereas newer treatments were evaluated using treat‐through designs.
Christopher Ma, Marla Dubinsky, Gil Y. Melmed, Namita Joshi, Jenny Griffith, Fernando Aponte, Brooke Kim, Eric B. Collins, Kristen Westerhoff, Remo Panaccione   +9 more
wiley   +1 more source

Emergence of Vitiligo during Treatment with Risankizumab-Rzaa for Plaque Psoriasis: A Case Report

Case Reports in Dermatology
Introduction: Risankizumab-rzaa (Skyrizi) is a humanized monoclonal antibody (IgG1) approved for the treatment of severe plaque psoriasis.
Kevin V. Thomas, Jennifer M. Tran, Lisa M. Cotter   +2 more
doaj   +1 more source

Impact of Vitamin D Sufficiency on Clinical Outcomes in Patients With IBD Treated With Biologics: A Summary of Observational and Interventional Data

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Vitamin D is increasingly recognised as a modifiable factor influencing immune responses in chronic inflammatory diseases. This short report examines the relationship between vitamin D status and therapeutic outcomes of biologics in patients with inflammatory bowel disease.
Karolina Siayor‐Pietrzak, Aysegül Aksan, Elisa Müller, Jürgen Stein   +3 more
wiley   +1 more source

Early and Sustained Comprehensive Symptom Control, Including Bowel Urgency and Fatigue, With Mirikizumab in Crohn's Disease: An Exploratory Post Hoc Analysis of the Phase 3 VIVID‐1 Study

JCC Plus, Volume 1, Issue 5, September 2026.
ABSTRACT Background and Aims In this exploratory post hoc analysis of the phase 3 VIVID‐1 (NCT03926130) study, we evaluate early and sustained treatment effects of mirikizumab on individual disruptive CD symptoms—stool frequency (SF), abdominal pain (AP), bowel urgency (BU) and fatigue—in non‐biologic‐failed (NBF) and biologic‐failed (BF) patients and ...
Axel Dignass, Silvio Danese, Jessica R. Allegretti, Sami Hoque, Minhu Chen, Katsuyoshi Matsuoka, Iago Rodríguez‐Lago, Sebastian Maier, Emily Hon, Chunyuan Liu, Guanglei Yu, Isabel Redondo, Bruce E. Sands   +12 more
wiley   +1 more source

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling

Frontiers in Immunology
IL-23 is implicated in the pathogenesis of immune-mediated inflammatory diseases, and myeloid cells that express Fc gamma receptor 1 (FcγRI or CD64) on their surface have been recently identified as a primary source of IL-23 in inflamed tissue.
Kacey L. Sachen, Deepa Hammaker, Indra Sarabia, Brian Stoveken, John Hartman, Kristin L. Leppard, Nicholas A. Manieri, Phuc Bao, Carrie Greving, Eilyn R. Lacy, Matthew DuPrie, Joshua Wertheimer, Janise D. Deming, Joseph Brown, Amy Hart, He (Hurley) Li, Tom C. Freeman, Brice Keyes, Kristen Kohler, Ian White, Nathan Karpowich, Ruth Steele, M. Merle Elloso, Steven Fakharzadeh, Kavitha Goyal, Frédéric Lavie, Maria T. Abreu, Matthieu Allez, Raja Atreya, Robert Bissonnette, Kilian Eyerich, Kilian Eyerich, James G. Krueger, Dennis McGonagle, Iain B. McInnes, Christopher Ritchlin, Anne M. Fourie   +36 more
doaj   +1 more source

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait, Anna Cargnoni, Franco Scaldaferri, Loris Lopetuso, Antonietta Rosa Silini, Ornella Parolini   +5 more
wiley   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1449-1459, September 2026.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Durability of response to icotrokinra for high‐impact site psoriasis: 1‐year ICONIC‐TOTAL findings

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1502-1514, September 2026.
Participants with at least moderate scalp, genital or hand/foot psoriasis receiving once‐daily oral icotrokinra achieved high, durable rates of overall and high‐impact site psoriasis clearance, showed substantial nail psoriasis improvement and exhibited no safety signals through 1 year, supporting icotrokinra use for long‐term management of high‐impact
Richard B. Warren, Melinda Gooderham, Edward Lain, Robert Bissonnette, Yu‐Huei Huang, Julien Ringuet, Matthias Hoffmann, Andreas Pinter, Joseph F. Merola, Jessica H. Rubens, Dorothy Fan, Ming‐Chun Hsu, Shu Li, Ya‐Wen Yang, Cynthia M. C. DeKlotz, Eingun James Song   +15 more
wiley   +1 more source

Drug‐Induced Vitiligo: FDA Adverse Events Reporting System (FAERS) and Canada Vigilance Adverse Reaction (CAVR) Database Analysis and Literature Review

Journal of Cosmetic Dermatology, Volume 25, Issue 9, September 2026.
ABSTRACT Background Vitiligo is a common chronic acquired pigmentation disease, that usually occurs with an asymptomatic whitish patch or macule. Although previous studies have reported several cases of drug‐induced vitiligo, there are few comprehensive studies determining the drugs that induce vitiligo.
Yuhao Li, Yi Ou, Luyue Chang, Ruiyao Wang, Xinyi Shao, Jingbo Zhang, Jin Chen   +6 more
wiley   +1 more source

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)

Frontiers in Immunology
IntroductionThe development of several effective biological drugs for moderate-to-severe plaque psoriasis has dramatically changed the lives of patients.
Luigi Gargiulo, Luigi Gargiulo, Luciano Ibba, Luciano Ibba, Piergiorgio Malagoli, Anna Balato, Federico Bardazzi, Martina Burlando, Carlo G. Carrera, Giovanni Damiani, Giovanni Damiani, Paolo Dapavo, Valentina Dini, Francesca M. Gaiani, Giampiero Girolomoni, Claudio Guarneri, Claudia Lasagni, Francesco Loconsole, Angelo V. Marzano, Angelo V. Marzano, Matteo Megna, Santo R. Mercuri, Santo R. Mercuri, Massimo Travaglini, Antonio Costanzo, Antonio Costanzo, Alessandra Narcisi   +26 more
doaj   +1 more source